Fineline Cube

Follow:
14420 Articles
Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation
CompanyDrug

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation

Shanghai Pharmaceutical and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access
CompanyDeals

Shanghai Pharmaceuticals and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access

China Medical System's Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use
CompanyDrug

China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting
CompanyDrug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

AbbVie's Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson's Disease
CompanyDrug

AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease

Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment
CompanyDrug

Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency
Policy / Regulatory

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange
CompanyDeals

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
CompanyDrug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Antengene's Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024
CompanyDrug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024

Lee's Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments
CompanyDrug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao
Policy / Regulatory

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao